Compare · GHRS vs JNJ
GHRS vs JNJ
Side-by-side comparison of GH Research PLC (GHRS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GHRS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $658.24B, about 332.0x GHRS ($1.98B).
- Over the past year, GHRS is up 115.0% and JNJ is up 54.8% - GHRS leads by 60.2 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 6 for GHRS).
- JNJ has more recent analyst coverage (25 ratings vs 14 for GHRS).
- Company
- GH Research PLC
- Johnson & Johnson
- Price
- $28.85+2.71%
- $273.23+0.07%
- Market cap
- $1.98B
- $658.24B
- 1M return
- +3.70%
- +2.75%
- 1Y return
- +114.98%
- +54.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 11
- Recent ratings
- 14
- 25
GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest GHRS
- Amendment: SEC Form SCHEDULE 13G/A filed by GH Research PLC
- SEC Form 4 filed by Director Moore Duncan
- SEC Form 4 filed by Director Hanley Dermot John
- SEC Form 4 filed by Director Forer Michael
- SEC Form 6-K filed by GH Research PLC
- GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
- Wells Fargo initiated coverage on GH Research PLC with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Latest JNJ
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One